| Revenue growth | 23.7% YoY in Q1FY27; 32% CAGR (FY23-26). |
|---|---|
| Margins | Adjusted EBITDA margin expanded 120 bps YoY to 23.1%. |
| Demand visibility | High; driven by diabetes, hypertension, and dialysis under-penetration. |
| Management confidence | Strong; citing India platform strength and operating leverage. |
Growth
Adjusted EBITDA grew 30.7% YoY to ₹65.1 Cr; Adjusted PAT rose 41.7% YoY to ₹36.8 Cr.
Outlook
Targeting high growth in India Tier 2/3 cities and international expansion in Philippines, Uzbekistan, and KSA.
Risks
High reliance on renal nurse availability; international market entry risks via JVs/acquisitions; competitive bidding for PPP tenders.
Last quarter's promises, checked
Delivered
- Guided 15-20% revenue CAGR → delivered 23.7% YoY (= BEAT)
- Guided 40-50 India clinic additions → delivered 12-15% guest growth (= BEAT)
- Guided international expansion focus → delivered 45% revenue mix (= BEAT)
Partly delivered
- Guided 10-15 Philippines roll-ups → delivered 7 acquisitions in Q1 (= PARTIAL)
Investor Presentation filed with NSE, NSE: NEPHROPLUS. Summary written with AI assistance from the document.
Nephrocare Health Services Ltd: key numbers
- Share price
- ₹696.65
- Market cap
- ₹6,990 Cr
- Revenue (annual)
- ₹998.8 Cr
- Net profit (annual)
- ₹76.84 Cr
- P/E (TTM)
- 82.1×Sector 57.8×
- Promoter holding
- 63.85%+0.00% QoQ
- FII holding
- 8.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nephrocare Health Services Ltd
All →Nephrocare Health Services Credit Rating
India Ratings upgraded Nephrocare Health Services' long-term bank loan facilities to IND AA-/Stable. The agency also affirmed the company's short-term credit ratings.
Nephrocare Health Services Merger & Restructuring
Nephrocare Health Services Ltd announced the rationalisation and consolidation of its step-down subsidiaries in the Philippines. This internal reorganization streamlines the group's existing structure.
Nephrocare Health Services Merger & Restructuring Worth ₹10.25 Cr
Nephrocare's Philippines subsidiary acquired a dialysis center from Renal One Dialysis Corp for ≈₹10.25 Cr. The asset transfer expands the company's dialysis network.
- Value
- ₹10.25 Cr
- dialysis center acquired
- 1 dialysis centers
Nephrocare Health Services Acquisition Worth ₹10.25 Cr
Nephrocare's Philippines subsidiary is acquiring a dialysis center from Renal One Dialysis Corp. for a consideration of ₹10.25 crore.
- Value
- ₹10.25 Cr
Nephrocare Health Services Employee Stock Options
Nephrocare Health Services granted 4,01,362 employee stock options at an exercise price of ₹230 per share. These options are issued under the NephroPlus Employee Stock Option Scheme 2026.
Nephrocare Health Services Earnings Call Transcript: Key Takeaways
Nephrocare delivered robust 23.7% revenue growth driven by international expansion and volume gains. While margins improved via operating leverage, high working capital cycles and binary outcomes in tender markets like Saudi Arabia remain key risks.
- Call
- Guides 18% growth